SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Wise P.) "

Sökning: WFRF:(Wise P.)

  • Resultat 1-10 av 154
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  •  
7.
  • Ruilope, LM, et al. (författare)
  • Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
  • 2019
  • Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
  • Tidskriftsartikel (refereegranskat)abstract
    • <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
  •  
8.
  • van Haarlem, M. P., et al. (författare)
  • LOFAR : The LOw-Frequency ARray
  • 2013
  • Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 556, s. 1-53
  • Tidskriftsartikel (refereegranskat)abstract
    • LOFAR, the LOw-Frequency ARray, is a new-generation radio interferometer constructed in the north of the Netherlands and across europe. Utilizing a novel phased-array design, LOFAR covers the largely unexplored low-frequency range from 10–240 MHz and provides a number of unique observing capabilities. Spreading out from a core located near the village of Exloo in the northeast of the Netherlands, a total of 40 LOFAR stations are nearing completion. A further five stations have been deployed throughout Germany, and one station has been built in each of France, Sweden, and the UK. Digital beam-forming techniques make the LOFAR system agile and allow for rapid repointing of the telescope as well as the potential for multiple simultaneous observations. With its dense core array and long interferometric baselines, LOFAR achieves unparalleled sensitivity and angular resolution in the low-frequency radio regime. The LOFAR facilities are jointly operated by the International LOFAR Telescope (ILT) foundation, as an observatory open to the global astronomical community. LOFAR is one of the first radio observatories to feature automated processing pipelines to deliver fully calibrated science products to its user community. LOFAR’s new capabilities, techniques and modus operandi make it an important pathfinder for the Square Kilometre Array (SKA). We give an overview of the LOFAR instrument, its major hardware and software components, and the core science objectives that have driven its design. In addition, we present a selection of new results from the commissioning phase of this new radio observatory.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 154
Typ av publikation
tidskriftsartikel (144)
forskningsöversikt (7)
konferensbidrag (3)
Typ av innehåll
refereegranskat (146)
övrigt vetenskapligt/konstnärligt (8)
Författare/redaktör
Nielsen, Niklas (74)
Friberg, Hans (66)
Cronberg, Tobias (56)
Hassager, Christian (40)
Kjaergaard, Jesper (38)
Wise, Matt P (34)
visa fler...
Horn, Janneke (33)
Erlinge, David (32)
Stammet, Pascal (31)
Lilja, Gisela (30)
Orru, E. (28)
Hoeft, M. (28)
Best, P. (27)
Heald, G. (27)
Ferrari, C. (26)
de Gasperin, F. (26)
van Weeren, R. J. (26)
Brüggen, M. (26)
Pellis, Tommaso (25)
Pizzo, R. (25)
Wucknitz, O. (25)
Bonafede, A. (25)
Falcke, H. (25)
Ciardi, B. (24)
Dankiewicz, Josef (24)
Steinmetz, M. (24)
Wanscher, Michael (24)
Garrett, M. A. (24)
Ullén, Susann (23)
Hovdenes, Jan (23)
Breitling, F. (23)
Pandey-Pommier, M. (23)
Kuper, G. (23)
Anderson, J (22)
Conway, John, 1963 (22)
Bentum, M. J. (22)
McKean, J. P. (22)
Reich, W. (22)
Zarka, P. (22)
Frieswijk, W. (22)
Kuniyoshi, M. (22)
Sluman, J. (22)
Bernardi, G. (21)
Undén, Johan (21)
Bell, M. E. (21)
Smirnov, O. (21)
Tagger, M. (21)
Kondratiev, V. I. (21)
Maat, P. (21)
Tang, Y. (21)
visa färre...
Lärosäte
Lunds universitet (75)
Karolinska Institutet (40)
Chalmers tekniska högskola (29)
Göteborgs universitet (21)
Uppsala universitet (16)
Linnéuniversitetet (16)
visa fler...
Kungliga Tekniska Högskolan (7)
Linköpings universitet (5)
Stockholms universitet (3)
Umeå universitet (1)
Örebro universitet (1)
Malmö universitet (1)
Högskolan i Borås (1)
visa färre...
Språk
Engelska (154)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (87)
Naturvetenskap (42)
Teknik (3)
Samhällsvetenskap (3)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy